FOLD Stock Price Today (April 2026) — Amicus Therapeutics, Inc. Analysis & Key Metrics 2026-04-02
Amicus Therapeutics, Inc. (FOLD) is trading at $14.46, up 0.17% today (as of April 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $14.50 (0.2% upside).
- Volatility remains elevated (1.80% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (23.70% YoY) alongside significant competitive pressures.
FOLD Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Amicus Therapeutics, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $4.68B
P/E Ratio
Forward P/E: 17.63
Revenue Growth
Year over Year
Analyst Target
+0.2% upside potential
Key Investor Questions About FOLD
What investors need to know before buying
Based on current market data, FOLD presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 64.36)
- Fundamentals say: Caution warranted (high leverage concerns)
FOLD's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for FOLD investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $442.36M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, FOLD stock traded between $5.51 and $14.46—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 1.80% annualized volatility and β=0.48, the stock exhibits low sensitivity to market moves—making FOLD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Here is Why BioMarin (BMRN) is Projected to Rally
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 best stocks that recently issued new debt. On March 11, Bank of America Securities reduced its price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from $97 to $85. The firm maintained a Buy rating on the stock, which now yields an adjusted upside of almost 54% despite […]
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return
Why Amicus Therapeutics is on investors’ radar today Amicus Therapeutics (FOLD) has drawn attention after recent share performance data highlighted a 71% total return over the past year, prompting closer scrutiny of how its rare disease portfolio and fundamentals align with current pricing. See our latest analysis for Amicus Therapeutics. While the recent 1-day and 7-day share price returns of around 0% suggest a pause, the 1-year total shareholder return of about 71% points to strong...
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
On Thursday, Tarsus Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 76 to 82. Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score.
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside
Why Amicus Therapeutics stands out today Amicus Therapeutics (FOLD) has drawn attention recently as investors weigh its current share price of US$14.37 against the company’s rare disease portfolio, revenue of US$634.21 million, and net loss of US$27.11 million. See our latest analysis for Amicus Therapeutics. At a share price of US$14.37, Amicus Therapeutics has seen a 32.08% 3 month share price return, while its 1 year total shareholder return of 61.46% contrasts with more modest multi year...
Viking Therapeutics Stock Gets RS Rating Upgrade
Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Rice Hall James Loads Up on BIRK With 466,000 Shares Bought
Birkenstock sells premium footwear via global channels, reaching comfort-focused consumers across major international markets.
Rice Hall James Buys QuidelOrtho Stock
QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings.
Frequently Asked Questions
Common investor questions about Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD) is currently trading at $14.46. The RSI (14-day) is at 64.4, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $14.50 implies 0.2% upside from current levels. Volatility is low at 1.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amicus Therapeutics, Inc. (FOLD): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 17.63. Price-to-Book is 16.37. Price-to-Sales is 7.15. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 5 analysts covering FOLD, the consensus price target is $14.50. This represents a 0.2% upside from the current price of $14.46. The range spans from a low target of $14.50 to a high target of $14.50, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Amicus Therapeutics, Inc. (FOLD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Amicus Therapeutics, Inc. (FOLD) investors include: 1. Elevated debt levels (D/E ratio of 161.30) which could pressure margins in a rising rate environment. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amicus Therapeutics, Inc.'s (FOLD) current debt and financial health profile: Total debt stands at $442.36M. The debt-to-equity ratio is 161.30, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 2.84, indicating strong short-term liquidity. The quick ratio is 1.72. The company holds $293.54M in cash and equivalents. Free cash flow is positive at $47.84M, providing a cushion for debt servicing and shareholder returns.